Deficient mismatch repair colon cancer
Showing 1 - 25 of >10,000
Colon Cancer, DMMR Colorectal Cancer Trial (Dostarlimab)
Not yet recruiting
- Colon Cancer
- DMMR Colorectal Cancer
- (no location specified)
Feb 4, 2022
MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)
Not yet recruiting
- MSI-H
- IBI310
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 26, 2023
Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)
Not yet recruiting
- Endometrial Neoplasms
- Endometrial Cancer
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System
Mar 21, 2023
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Trial in Kashiwa (HRO761,
Recruiting
- MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
- HRO761
- +2 more
-
Kashiwa, Chiba, JapanNovartis Investigative Site
May 2, 2023
Recurrent Endometrial Cancer, Solid Tumors Trial in Pittsburgh (pembrolizumab, Sitravatinib)
Recruiting
- Recurrent Endometrial Cancer
- Solid Tumors
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 12, 2022
Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))
Active, not recruiting
- Colorectal Cancer
- IBI310 (anti-CTLA-4 antibody)
- Sintilimab(anti-PD-1 antibody)
-
Beijing, ChinaBeijing cancer hospital
Sep 15, 2022
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer Trial in Houston (Tecentriq 1200 MG in 20 ML Injection +
Not yet recruiting
- Stage I Colon Cancer
- +2 more
- Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
- +2 more
-
Houston, TexasBaylor College of Medicine
May 22, 2023
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer
Active, not recruiting
- Microsatellite Unstable Colorectal Cancer
- +3 more
- Ipilimumab
- +4 more
-
Gilbert, Arizona
- +31 more
Dec 21, 2021
Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency Trial in New Brunswick (drug, other,
Recruiting
- Epstein-Barr Virus Positive
- +10 more
- Capecitabine
- +3 more
-
Atlanta, Georgia
- +2 more
Dec 10, 2022
Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)
Recruiting
- Locally Advanced Malignant Solid Neoplasm
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Mar 22, 2022
Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)
Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab
Not yet recruiting
- Colorectal Cancer
- +3 more
- Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
-
ZhengZhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023
Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)
Not yet recruiting
- Adenocarcinoma - GEJ
- Gastric Adenocarcinoma
- (no location specified)
Sep 26, 2023
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma Trial in Houston
Active, not recruiting
- Advanced Colorectal Carcinoma
- +24 more
- Danvatirsen
- Durvalumab
-
Houston, TexasM D Anderson Cancer Center
Oct 20, 2022
Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in
Recruiting
- Recurrent Endometrial Adenocarcinoma
- +8 more
- Ipilimumab
- Nivolumab
-
Iowa City, Iowa
- +9 more
Jan 27, 2023
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
Endometrial Cancer Trial (Anlotinib + Camrelizumab)
Not yet recruiting
- Endometrial Cancer
- Anlotinib + Camrelizumab
- (no location specified)
Sep 26, 2022
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,
Not yet recruiting
- Diffuse Astrocytoma, IDH-Mutant
- +20 more
- NEO212 Oral Capsule
- +8 more
- (no location specified)
Sep 18, 2023
Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)
Not yet recruiting
- Colorectal Cancer Stage IV
- +2 more
- (no location specified)
Jun 19, 2022
Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant
Recruiting
- Colorectal Cancer
- +3 more
- Neoadjuvant therapy with PD-L1 inhibitor
-
Guangzhou, Guangdong, Chinathe Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022
MSI-H Colorectal Cancer Trial (colorectal resection)
Completed
- MSI-H Colorectal Cancer
- colorectal resection
- (no location specified)
May 22, 2023
Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)
Not yet recruiting
- Metastatic Colorectal Cancer
- HX008
- Investigator's Choice Chemotherapy
-
Hefei, Anhui, China
- +9 more
Dec 8, 2022